Out of limbo, Sarepta is raising $225M and taking bids on a priority voucher as it revs up marketing
After sitting in regulatory limbo for most of the year, Sarepta execs have a long to-do list in hand as they roll out their Duchenne …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
